EWING, N.J., June 13, 2017 /PRNewswire/ -- Essential Pharmaceuticals, LLC Chief Science Officer, Dr. Adam Elhofy, will be discussing mechanisms to increase antibody titer and present new data on Cell-Ess Universal Titer Boost at BIO International Convention in San Diego June 19-22 and Cell Culture & Cell Therapy: Bioprocessing Conference in Philadelphia June 26-27. BIO International Convention attracts 16,000+ attendees from 5,000+ companies including the leading biotech companies, top 25 pharma companies, top 20 CROs and CMOs, more than 300 academic institutions, etc. Cell Culture & Cell Therapy: Bioprocessing Conference is a unique platform to establish the reproducible and robust manufacturing processes for the production of stable cell culture and therapeutic cells.
Cell-Ess is the world’s first universal titer boost and enhancer that works across a wide range of media systems. Cell-Ess used as a feed improves consistency in glycan patterns while increasing protein titer by 20-50% compared to control in various previously optimized cell lines and media schemes. The increase is observed in glass shake flasks, single-use Wave BioreactorsTM, and ambr® cell culture systems. In a 5-minute video, Essential Pharmaceuticals CEO Allan Weber and Dr. Elhofy discuss why Cell-Ess was invented, what makes it different from traditional media supplements and feeds, and the impact on bioproduction productivity, efficiency and cost management.
Dr. Elhofy will discuss bioprocessing challenges and present data during his talk titled “Increasing Cell Productivity and Quality in mAb Production by Focusing on a Novel Target” at BIO on June 20th 2-2:20 pm at the BPI Theater, Booth #1319. Additionally, he will present his talk titled “Glycolytic Complexity and Pattern Consistency and Titer Can Be Improved Using Novel Lipid Delivery in Cell-Ess” at Cell Culture & Cell Therapy Conference on June 26th 10:20-10:50 am.
“Our findings confirm numerous previous studies that Cell-Ess increases protein titer and productivity in multiple cell lines and media systems,” says Dr. Elhofy. “Additionally, this new data demonstrates that Cell-Ess simultaneously improves consistency of glycosylation patterns and increases the amount of higher glycoforms or galactosylation.”
“Cell-Ess fills a previously unmet need in bioprocessing media,” says Allan. “The patented technology to deliver critical components to cells results in improved performance regardless of the base media or feed system.”
About Essential Pharmaceuticals
Essential Pharmaceuticals provides surgeons, biopharmaceutical manufacturers and medical researchers tools to bring performance, convenience, and control to enhance production, drug discovery and advancement of basic research. Established in 2006, Essential Pharmaceuticals supports the preservation and growth of human systems through expanding its product development to further medical treatments for mankind.
For more information on Essential Pharmaceuticals, visit www.EssentialPharma.com or contact Denise Weber at the corporate office: 1-844-Ess-Prod Email: 163954@email4pr.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/essential-pharmaceuticals-to-present-on-increasing-antibody-titer-without-impacting-glycosylation-at-bio-international-convention-and-cell-culture--cell-therapy-conference-300472916.html
